Mechanisms of nifedipine-downregulated CD40L/sCD40L signaling in collagen stimulated human platelets

Tso Hsiao Chen, Ching Yu Shih, Wen Lin Hsu, Tz Chong Chou

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The platelet-derived soluble CD40L (sCD40L) release plays a critical role in the development of atherosclerosis. Nifedipine, a dihydropyridine-based L-type calcium channel blocker (CCB), has been reported to have an anti-atherosclerotic effect beyond its blood pressure-lowering effect, but the molecular mechanisms remain unclear. The present study was designed to investigate whether nifedipine affects sCD40L release from collagen-stimulated human platelets and to determine the potential role of peroxisome proliferator-activated receptor-β/γ (PPAR-β/γ). We found that treatment with nifedipine significantly inhibited the platelet surface CD40L expression and sCD40L release in response to collagen, while the inhibition was markedly reversed by blocking PPAR-β/γ activity with specific antagonist such as GSK0660 and GW9662. Meanwhile, nifedipine also enhanced nitric oxide (NO) and cyclic GMP formation in a PPAR-β/γ-dependent manner. When the NO/cyclic GMP pathway was suppressed, nifedipine-mediated inhibition of sCD40L release was abolished significantly. Collagen-induced phosphorylation of p38MAPK, ERK1/2 and HSP27, matrix metalloproteinase-2 (MMP-2) expression/activity and reactive oxygen species (ROS) formation were significantly inhibited by nifedipine, whereas these alterations were all attenuated by co-treatment with PPAR-β/γ antagonists. Collectively, these results demonstrate that PPAR-β/γ-dependent pathways contribute to nifedipine-mediated downregulation of CD40L/sCD40L signaling in activated platelets through regulation of NO/ p38MAPK/ERK1/2/HSP27/MMP-2 signalings and provide a novel mechanism regarding the anti-atherosclerotic effect of nifedipine.

Original languageEnglish
Article numbere0127054
JournalPLoS One
Volume10
Issue number5
DOIs
Publication statusPublished - May 13 2015

Fingerprint

CD40 Ligand
Nifedipine
Platelets
collagen
Collagen
Blood Platelets
Down-Regulation
Peroxisome Proliferator-Activated Receptors
nitric oxide
cyclic GMP
gelatinase A
antagonists
Nitric Oxide
Matrix Metalloproteinase 2
Cyclic GMP
calcium channel blockers
atherosclerosis
blood pressure
reactive oxygen species
phosphorylation

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Mechanisms of nifedipine-downregulated CD40L/sCD40L signaling in collagen stimulated human platelets. / Chen, Tso Hsiao; Shih, Ching Yu; Hsu, Wen Lin; Chou, Tz Chong.

In: PLoS One, Vol. 10, No. 5, e0127054, 13.05.2015.

Research output: Contribution to journalArticle

Chen, Tso Hsiao ; Shih, Ching Yu ; Hsu, Wen Lin ; Chou, Tz Chong. / Mechanisms of nifedipine-downregulated CD40L/sCD40L signaling in collagen stimulated human platelets. In: PLoS One. 2015 ; Vol. 10, No. 5.
@article{2d28b555c8054c60b97e40314ff5de2d,
title = "Mechanisms of nifedipine-downregulated CD40L/sCD40L signaling in collagen stimulated human platelets",
abstract = "The platelet-derived soluble CD40L (sCD40L) release plays a critical role in the development of atherosclerosis. Nifedipine, a dihydropyridine-based L-type calcium channel blocker (CCB), has been reported to have an anti-atherosclerotic effect beyond its blood pressure-lowering effect, but the molecular mechanisms remain unclear. The present study was designed to investigate whether nifedipine affects sCD40L release from collagen-stimulated human platelets and to determine the potential role of peroxisome proliferator-activated receptor-β/γ (PPAR-β/γ). We found that treatment with nifedipine significantly inhibited the platelet surface CD40L expression and sCD40L release in response to collagen, while the inhibition was markedly reversed by blocking PPAR-β/γ activity with specific antagonist such as GSK0660 and GW9662. Meanwhile, nifedipine also enhanced nitric oxide (NO) and cyclic GMP formation in a PPAR-β/γ-dependent manner. When the NO/cyclic GMP pathway was suppressed, nifedipine-mediated inhibition of sCD40L release was abolished significantly. Collagen-induced phosphorylation of p38MAPK, ERK1/2 and HSP27, matrix metalloproteinase-2 (MMP-2) expression/activity and reactive oxygen species (ROS) formation were significantly inhibited by nifedipine, whereas these alterations were all attenuated by co-treatment with PPAR-β/γ antagonists. Collectively, these results demonstrate that PPAR-β/γ-dependent pathways contribute to nifedipine-mediated downregulation of CD40L/sCD40L signaling in activated platelets through regulation of NO/ p38MAPK/ERK1/2/HSP27/MMP-2 signalings and provide a novel mechanism regarding the anti-atherosclerotic effect of nifedipine.",
author = "Chen, {Tso Hsiao} and Shih, {Ching Yu} and Hsu, {Wen Lin} and Chou, {Tz Chong}",
year = "2015",
month = "5",
day = "13",
doi = "10.1371/journal.pone.0127054",
language = "English",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

TY - JOUR

T1 - Mechanisms of nifedipine-downregulated CD40L/sCD40L signaling in collagen stimulated human platelets

AU - Chen, Tso Hsiao

AU - Shih, Ching Yu

AU - Hsu, Wen Lin

AU - Chou, Tz Chong

PY - 2015/5/13

Y1 - 2015/5/13

N2 - The platelet-derived soluble CD40L (sCD40L) release plays a critical role in the development of atherosclerosis. Nifedipine, a dihydropyridine-based L-type calcium channel blocker (CCB), has been reported to have an anti-atherosclerotic effect beyond its blood pressure-lowering effect, but the molecular mechanisms remain unclear. The present study was designed to investigate whether nifedipine affects sCD40L release from collagen-stimulated human platelets and to determine the potential role of peroxisome proliferator-activated receptor-β/γ (PPAR-β/γ). We found that treatment with nifedipine significantly inhibited the platelet surface CD40L expression and sCD40L release in response to collagen, while the inhibition was markedly reversed by blocking PPAR-β/γ activity with specific antagonist such as GSK0660 and GW9662. Meanwhile, nifedipine also enhanced nitric oxide (NO) and cyclic GMP formation in a PPAR-β/γ-dependent manner. When the NO/cyclic GMP pathway was suppressed, nifedipine-mediated inhibition of sCD40L release was abolished significantly. Collagen-induced phosphorylation of p38MAPK, ERK1/2 and HSP27, matrix metalloproteinase-2 (MMP-2) expression/activity and reactive oxygen species (ROS) formation were significantly inhibited by nifedipine, whereas these alterations were all attenuated by co-treatment with PPAR-β/γ antagonists. Collectively, these results demonstrate that PPAR-β/γ-dependent pathways contribute to nifedipine-mediated downregulation of CD40L/sCD40L signaling in activated platelets through regulation of NO/ p38MAPK/ERK1/2/HSP27/MMP-2 signalings and provide a novel mechanism regarding the anti-atherosclerotic effect of nifedipine.

AB - The platelet-derived soluble CD40L (sCD40L) release plays a critical role in the development of atherosclerosis. Nifedipine, a dihydropyridine-based L-type calcium channel blocker (CCB), has been reported to have an anti-atherosclerotic effect beyond its blood pressure-lowering effect, but the molecular mechanisms remain unclear. The present study was designed to investigate whether nifedipine affects sCD40L release from collagen-stimulated human platelets and to determine the potential role of peroxisome proliferator-activated receptor-β/γ (PPAR-β/γ). We found that treatment with nifedipine significantly inhibited the platelet surface CD40L expression and sCD40L release in response to collagen, while the inhibition was markedly reversed by blocking PPAR-β/γ activity with specific antagonist such as GSK0660 and GW9662. Meanwhile, nifedipine also enhanced nitric oxide (NO) and cyclic GMP formation in a PPAR-β/γ-dependent manner. When the NO/cyclic GMP pathway was suppressed, nifedipine-mediated inhibition of sCD40L release was abolished significantly. Collagen-induced phosphorylation of p38MAPK, ERK1/2 and HSP27, matrix metalloproteinase-2 (MMP-2) expression/activity and reactive oxygen species (ROS) formation were significantly inhibited by nifedipine, whereas these alterations were all attenuated by co-treatment with PPAR-β/γ antagonists. Collectively, these results demonstrate that PPAR-β/γ-dependent pathways contribute to nifedipine-mediated downregulation of CD40L/sCD40L signaling in activated platelets through regulation of NO/ p38MAPK/ERK1/2/HSP27/MMP-2 signalings and provide a novel mechanism regarding the anti-atherosclerotic effect of nifedipine.

UR - http://www.scopus.com/inward/record.url?scp=84929340271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929340271&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0127054

DO - 10.1371/journal.pone.0127054

M3 - Article

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 5

M1 - e0127054

ER -